Marla B Sultan
Affiliation: Pfizer Global Research and Development
- Epidemiology, risk factors and management of paediatric diabetic retinopathyMarla B Sultan
Pfizer Inc, New York, NY 10017, USA
Br J Ophthalmol 96:312-7. 2012..Both pathophysiology and treatment in paediatric populations are essentially the same as described for adult populations, with treatment usually not required until adulthood is reached...
- Understanding the importance of IOP variables in glaucoma: a systematic reviewMarla B Sultan
New York Eye and Ear Infirmary, New York, New York, USA
Surv Ophthalmol 54:643-62. 2009..to assess long-term IOP fluctuation in patients under stable treatment (across days or visits)? and 5) Should therapy choices be influenced by properties of different treatment options relative to short- or long-term IOP fluctuation?..
- A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edemaMarla B Sultan
Pfizer Inc, New York, New York 10017, USA
Ophthalmology 118:1107-18. 2011..To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0.3 mg versus sham injections in subjects with diabetic macular edema (DME) involving the center of the macula associated with vision loss not due to ischemia...
- A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitusTheresa Dombi
Pfizer Inc, Groton, CT, USA
BMC Ophthalmol 12:37. 2012..To evaluate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the treatment of neovascular age-related macular degeneration in subjects with or without diabetes mellitus...